| Post marketing adverse event reporting lists the following as
frequent events (occurring in numbers greater than 1 in 100):
Abnormal dreams, emotional lability (mood swings) and stupor.
It is unknown whether these events are related to exposure to glatiramer
acetate (Copaxone ®).
|
